GSK, Celgene cough up milestone payments

Share this article:

Epizyme announced Monday that its experimental orphan drug for acute leukemia, EPZ-5676, achieved its proof-of-concept milestone, triggering a $25-million payment from partner Celgene. The drug is for patients in whom the MLL gene is rearranged due to a chromosomal translocation or partial tandem duplication. The conditions result in “an increased expression of genes causing leukemia.”

The Cambridge, MA, company also scored $4 million from partner GlaxoSmithKline for a milestone payment associated with one of three histone methyltrasferase targets. The companies joined up in 2011 for a deal that includes up to $626 million in milestone payments and sales-based milestone payments of up to $270 million.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.